Kyoko Yamashita

Dr. Kyoko Yamashita

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
YYYuichi Yamada
Yuichi Yamada
IKIzumi Kinoshita
Izumi Kinoshita
KKKohashi Kenichi
Kohashi Kenichi
HYHidetaka Yamamoto
Hidetaka Yamamoto
TITakeshi Iwasaki
Takeshi Iwasaki
YOYoshinao Oda
Yoshinao Oda

7 April 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMiwa Tanaka
Miwa Tanaka
SCSurachada Chuaychob
Surachada Chuaychob
MHMizuki Homme
Mizuki Homme
YYYukari Yamazaki
Yukari Yamazaki
RLRuyin Lyu
Ruyin Lyu
TNTakuro Nakamura
Takuro Nakamura
Alveolar soft part sarcoma (ASPS) is a soft part malignancy affecting adolescents and young adults. ASPS is characterized by a highly integrated vascular network, and its high metastatic potential indicates the importance of ASPS’s prominent angiogenic activity. Here, we find that the expression of ASPSCR1::TFE3, the fusion transcription factor causatively associated with ASPS, is dispensable for in vitro tumor maintenance; however, it is required for in vivo tumor development via angiogenesis. ASPSCR1::TFE3 is frequently associated with super-enhancers (SEs) upon its DNA binding, and the loss of its expression induces SE-distribution dynamic modification related to genes belonging to the angiogenesis pathway. Using epigenomic CRISPR/dCas9 screening, we identify Pdgfb, Rab27a, Sytl2, and Vwf as critical targets associated with reduced enhancer activities due to the ASPSCR1::TFE3 loss. Upregulation of Rab27a and Sytl2 promotes angiogenic factor-trafficking to facilitate ASPS vascular network construction. ASPSCR1::TFE3 thus orchestrates higher ordered angiogenesis via modulating the SE activity.

27 October 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
KYKyoko Yamashita
Kyoko Yamashita
KKKenichi Kohashi
Kenichi Kohashi
YYYuichi Yamada
Yuichi Yamada
TITakeaki Ishii
Takeaki Ishii
YNYoshihiro Nishida
Yoshihiro Nishida
Shinya ToyokuniShinya Toyokuni
Shinya Toyokuni

22 May 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
MTMiwa Tanaka
Miwa Tanaka
MHMizuki Homme
Mizuki Homme
YTYasuyo Teramura
Yasuyo Teramura
KKKohei Kumegawa
Kohei Kumegawa
YYYukari Yamazaki
Yukari Yamazaki
TNTakuro Nakamura
Takuro Nakamura
Mesenchymal chondrosarcoma affects adolescents and young adults, and most cases usually have the HEY1::NCOA2 fusion gene. However, the functional role of HEY1-NCOA2 in the development and progression of mesenchymal chondrosarcoma remains largely unknown. This study aimed to clarify the functional role of HEY1-NCOA2 in transformation of the cell of origin and induction of typical biphasic morphology of mesenchymal chondrosarcoma. We generated a mouse model for mesenchymal chondrosarcoma by introducing HEY1-NCOA2 into mouse embryonic superficial zone (eSZ) followed by subcutaneous transplantation into nude mice. HEY1-NCOA2 expression in eSZ cells successfully induced subcutaneous tumors in 68.9% of recipients, showing biphasic morphologies and expression of Sox9 , a master regulator of chondrogenic differentiation. ChIP sequencing analyses indicated frequent interaction between HEY1-NCOA2 binding peaks and active enhancers. Runx2, which is important for differentiation and proliferation of the chondrocytic lineage, is invariably expressed in mouse mesenchymal chondrosarcoma, and interaction between HEY1-NCOA2 and Runx2 is observed using NCOA2 C-terminal domains. Although Runx2 knockout resulted in significant delay in tumor onset, it also induced aggressive growth of immature small round cells. Runx3, which is also expressed in mesenchymal chondrosarcoma and interacts with HEY1-NCOA2, replaced the DNA-binding property of Runx2 only in part. Treatment with the HDAC inhibitor panobinostat suppressed tumor growth both in vitro and in vivo, abrogating expression of genes downstream of HEY1-NCOA2 and Runx2. In conclusion, HEY1::NCOA2 expression modulates the transcriptional program in chondrogenic differentiation, affecting cartilage-specific transcription factor functions.

31 December 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
JKJunko Kunieda
Junko Kunieda
KYKyoko Yamashita
Kyoko Yamashita
YTYuki Togashi
Yuki Togashi
SBSatoko Baba
Satoko Baba
SSSeiji Sakata
Seiji Sakata
KTKengo Takeuchi
Kengo Takeuchi
Myxoid liposarcoma (MLPS) is genetically characterized by FUS‐DDIT3 or EWSR1‐DDIT3 gene fusion and the high frequency of hotspot mutations (C228T or C250T) in the promoter region of telomerase reverse transcriptase (TERT) that encodes the TERT protein. The latter leads to telomerase reactivation, a mechanism of telomere maintenance. Although the TERT promoter hotspot mutation is a poor prognostic factor in various tumors, its effect on MLPS has not been reported in detail. In the present study, we examined the clinicopathological characteristics, prognosis, and telomere maintenance mechanisms in 83 primary tumor samples of MLPS, which were resected surgically at the Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, from 2008 to 2020. TERT promoter hotspot mutations were observed in 77% (63/82) cases, and alternative lengthening of telomeres (ALT) was absent in all cases. Among the cases without TERT promoter hotspot mutations, TERT rearrangements, and minor point mutations in the TERT promoter region were found in 3 and 2 cases, respectively. TERT mRNA expression was observed consistently even in patients for whom no genomic TERT aberrations were detected, and the presence of TERT promoter hotspot mutation did not correlate significantly with either overall and metastasis‐free survival (P = .56, P = .83, respectively) or clinicopathological features. Therefore, patients with MLPS characteristically shows TERT expression and a high prevalence of TERT aberrations. Our findings suggest that TERT aberration is not prognostic factor, but might occur at an early stage and play a key role in tumorigenesis.

20 March 2023 in Histopathology
Verified
Journal Article
Closed access
KYKyoko Yamashita
Kyoko Yamashita
SBSatoko Baba
Satoko Baba
YTYuki Togashi
Yuki Togashi
ADAkito Dobashi
Akito Dobashi
KAKeisuke Ae
Keisuke Ae
KTKengo Takeuchi
Kengo Takeuchi